News

Spyre's anti-TL1A drug SPY072 hits Phase 2 goal in rheumatoid arthritis but effect too small to lead with

Spyre Therapeutics reported topline results on 25 August 2026 from the rheumatoid arthritis (RA) arm of its Phase 2 SKYWAY trial testing SPY072, an experimental antibody the company hopes patients could one day take as a twice-a-year or quarterly injection rather than the frequent dosing many current arthritis drugs require.

The headline: the drug worked, but not powerfully enough to build Spyre's RA strategy around it on its own. At 12 weeks, a low dose of SPY072 produced a statistically significant improvement over placebo on the trial's main yardstick (DAS28-CRP, a standard score of how active the disease is). On a widely used response measure, 58% of low-dose patients and 63% of high-dose patients saw meaningful improvement, versus 43% on placebo. But Spyre said the size of that benefit fell short of the bar it had set to prioritise developing SPY072 as a standalone RA treatment.

SPY072 blocks TL1A, a signalling protein that drives inflammation across several autoimmune conditions. Spyre framed the RA readout as evidence the whole approach works, and is pressing ahead: results in two related joint diseases (psoriatic arthritis and axial spondyloarthritis) are due in Q4 2026, and a combination with an anti-IL-17 drug in the skin condition hidradenitis suppurativa is expected in late 2027 or early 2028. The drug was well tolerated, with side-effect rates similar to placebo.

Source: Spyre Therapeutics (GlobeNewswire), 25 August 2026.

More top stories